Search results

714 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Social care guidelines Remove Social care guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter
COVID-19 rapid guidelines Remove COVID-19 rapid guidelines filter

Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]

Proposed [GID-HST10038] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Odevixibat (A 4250) for progressive familial intrahepatic cholestasis [ID1570]

Proposed [GID-HST10043] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818

Proposed [GID-HST10040] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]

Proposed [GID-HST10034] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Proposed [GID-HST10019] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

Proposed [GID-HST10039] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Avalglucosidase alfa for treating Pompe disease [ID3737]

Proposed [GID-HST10030] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

Proposed [GID-HST10037] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

In development [GID-NG10113] Expected publication date: 19 January 2022

Type

NICE guideline

Status

In development
Advocacy services for adults with health and social care needs

In development [GID-NG10156] Expected publication date: TBC

Type

NICE guideline

Status

In development
Adults with complex needs: social work interventions including assessment, care management and support

In development [GID-NG10145] Expected publication date: 27 April 2022

Type

NICE guideline

Status

In development
OTL-200 for treating metachromatic leukodystrophy [ID1666]

In development [GID-HST10028] Expected publication date: 13 August 2021

Type

Highly specialised technologies guidance

Status

In development
Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Givosiran for treating acute hepatic porphyria [ID1549]

In development [GID-HST10035] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

In development [GID-HST10032] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

In development [GID-HST10033] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]

In development [GID-TAG430] Expected publication date: 03 March 2021

Type

Technology appraisal guidance

Status

In development
Baricitinib for treating moderate to severe atopic dermatitis [ID1622]

In development [GID-TA10562] Expected publication date: 03 March 2021

Type

Technology appraisal guidance

Status

In development
Liposomal bupivacaine for treating postoperative pain [ID3799]

Proposed [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibalizumabtreating for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

Proposed [GID-TA10657] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Proposed [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]

Proposed [GID-TA10781] Expected publication date: 22 September 2021

Type

Technology appraisal guidance

Status

Proposed
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Proposed [GID-TA10655] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Proposed [GID-TA10660] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Proposed [GID-TA10741] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

Proposed [GID-TA10764] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Semaglutide for managing overweight and obesity [ID3850]

Proposed [GID-TA10765] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]

Proposed [GID-TA10782] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

Proposed [GID-TA10666] Expected publication date: 26 August 2021

Type

Technology appraisal guidance

Status

Proposed
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]

Proposed [GID-TA10676] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Proposed [GID-TA10763] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492) ID3777

Proposed [GID-TA10810] Expected publication date: 22 October 2021

Type

Technology appraisal guidance

Status

Proposed
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]

Proposed [GID-TA10749] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lasmiditan for treating acute migraine [ID3759]

Proposed [GID-TA10807] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Voxelotor for treating sickle cell disease [ID1403]

Proposed [GID-TA10505] Expected publication date: 10 August 2022

Type

Technology appraisal guidance

Status

Proposed
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]

Proposed [GID-TA10753] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active ankylosing spondylitis [ID3848]

Proposed [GID-TA10735] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tofacitinib for treating active ankylosing spondylitis [ID3865]

Proposed [GID-TA10771] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

Proposed [GID-TA10811] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]

Proposed [GID-TA10812] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]

Proposed [GID-TA10813] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]

Proposed [GID-TA10814] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed